Lead generation - Enhancing the success of drug discovery by investing in the hit to lead process

Combinatorial Chemistry and High Throughput Screening

Volumn 6, Issue 1, 2003, Pages 51-66

  Alanine, Alexander ^a   Nettekoven, Matthias ^a   Roberts, Edward ^a   Thomas, Andrew W ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Early ADME; Hit to lead; Hit validation; Lead Generation; Lead optimisation; Lead series identification; Medicinal chemistry; Multi dimensional optimisation

Indexed keywords

LEAD;

CHEMISTRY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; PRIORITY JOURNAL; REVIEW;

EID: 0037323146     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/1386207033329823     Document Type: Review

References (110)

1. (a) Dimasi, J. A. Clin. Pharmacol. Therap. 2001, 69, 297-307.
2. (b) Shah, N. D., Vermeulen, L. C., Santell, J. P., Hunkler, R. J., Hontz, K. Am. J. Health-System Pharm. 2002, 59, 131-142.
3. (a) Drews, J. Science 2000, 287, 1960-1964.
4. (b) Drews, J. Jürgen Drews discusses the future of the industry; Interviewed by Rebecca N. Lawrence, Drug Discovery Today 2001, 6, 338-341.
5. (a) Boguslavsky J. Drug Disc. & Develop. 2001, 4, 26-30.
6. (b) Goodnow, R. A., Jr. J. Cell. Biochem. 2001, Suppl. 37, 13-21.
7. (c) Wess, G., Urmann, M., Sickenberger, B. Angew. Chem. Int. Ed. Engl. 2001, 40, 3341-3350.
8. (d) Wess, G. Drug Discovery Today, 2002, 7, 533-535.
9. (a) Zall, M. Modern Drug Discovery 2001, 4, 36-38, 41-42.
10. (b) Ratti, E., Trist. D. Il Farmaco 2001, 56, 13-19.
11. (c) Adang, A. E. P., Hermkens, P. H. H. Current Med. Chem. 2001, 8, 985-998.
12. Smith A. Nature 2002, 418, 453-459.
13. (a) Langer, T., Hoffmann, R. D. Curr. Pharm. Design 2001, 7, 509-527.
14. (b) Good, A. C., Krystek, S. R., Mason, J. S. Drug Discovery Today 2000, 5, S61-S69.
15. (c) Burbaum, J., Tobal, G. M. Current Opin. Chem. Biol. 2002, 6, 427-433.
16. (d) Eglen, R. M., Schneider, G., Boehm, H.-J. Methods Princ. Med. Chem. 2000, 10, 1-14.
17. (e) Boehm, H.-J., Schneider, G. Methods Princ. Med. Chem. 2000, 10, 307-310.
18. (f) Bleicher, K. Curr. Med. Chem. 2002, 9, 2077-2084.
19. (a) Hunter, D. J. Cell. Biochem. 2001, Suppl. 37, 22-27.
20. (b) Michne, W. F. Pharm. News 1996, 3, 19-21.
21. (c) Campbell, S., Differding, E. Drug discovery strategies: from leads to drugs. Chim. Nouv. 2001, 19, 3347-3352.
22. (d) Tropsha, A., Reynolds, C. H. J. Mol. Graph. Mod. 2002, 20, 427-428.
23. (a) Boehm, H.-J., Boehringer, M., Bur, D., Gmuender, H., Huber, W., Klaus, W., Kostrewa, D., Kuehne, H.R., Luebbers, T.S., Meunier-Keller, N., Mueller, F. J. Med. Chem. 2000, 43, 2664-2674.
24. (b) Klebe, G., Gradler, U., Gruneberg, S., Kramer, O., Gohlke, H. Meth. Princ. Med. Chem. 2000, 10, 207-227.
25. (c) Good, A. C., Mason, J. S., Pickett, S. D. Meth. Princ. Med. Chem. 2000, 10, 131-159.
26. (d) Mason, J. S., Good, A. C., Martin, E. J. Curr. Pharm. Design 2001, 7, 567-597.
27. (d) Martin, Y. C., Kofron, J. L., Traphagen, L. M. J. Med. Chem. 2002, 45, 4350-4358.
28. (e) Bajorath, J. Curr. Drug Disc. 2002, 3, 24-28.
29. (f) Waszkowycz, B., Perkins, R. D. J., Sykes, R. A., Li, J. IBM Systems Journal 2001, 40, 360-376.
30. (a) Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., Kopple, K. D. J. Med. Chem. 2002, 45, 2615-2623.
31. (b) Sinko, P. J. Curr. Opin. Drug Disc. Devel. 1999, 2, 42-48.
32. (c) Lipinski, C. A. J. Pharm. Tox. Meth. 2001, 44, 235-249.
33. (d) Kariv, I., Rourik, R. A., Kassel, D. B., Chung, T. D. Y. Comb. Chem. High Throughput Screen. 2002, 5, 459-472.
34. (e) Masimirembwa, C. M., Thompson, R., Andersen, T. B. Comb. Chem. High Throughput Screen. 2001, 4, 245-263.
35. (a) DiMasi, J. A., Caglarcan, E., Wood-Armany, M. Pharmacogenomics 2001, 19, 753-66.
36. (b) Eddershaw, P. J., Beresford, A. P., Bayliss, M. K. Drug Discovery Today 2000, 5, 409-414.
37. (a) Dunn, D., Orlowski, M., McCoy, P., Gastgeb, F., Appell, K., Ozgur, L., Webb, M., Burbaum, J. J. Biomol. Screen. 2000, 5, 177-187.
38. (b) Andersson, P. M., Sjostrom, M., Wold, S., Lundstedt, T. J. Chemometrics 2001, 15, 353-369.
39. (a) Peng, J. W., Lepre, C. A., Fejzo, J., Abdul-Manan, N., Moore, J. M. Meth. Enzym. 2001, 338, 202-230.
40. (b) Moore, J. M. Biopolymers 1999, 51, 221-243.
41. (c) Heller, M., Kessler, H. Pure Appl. Chem. 2001, 73, 1429-1436.
42. (d) Schneider, G., Neidhart, W., Adam, G. Curr. Med. Chem. 2001, 1, 99-112.
43. (e) Malmqvist, M. Nature 1993, 361, 186-187.
44. (f) Nienaber, V. L., Richardson, P. L., Klighofer, V., Bouska, J. J., Giranda, V. L., Greer, J. Nature Biotechnol. 2000, 18, 1105-1108.
45. Parexel's Pharmaceutical R&D Statistical Sourcebook 2002, 102-103.
46. Definitions for hit, validated hit, lead and lead series are Roche in-house agreed upon terminology.
47. (a) Roche, O., Schneider, P., Zuegge, J., Guba, W., Kansy, M., Alanine, A., Bleicher, K., Danel, F., Gutknecht, E.-M., Rogers-Evans, M., Neidhart, W., Stalder, H., Dillon, M., Sjögren, E., Fotouhi, N., Gillespie, P., Goodnow, R., Harris, W., Jones, P., Taniguchi, M., Tsujii, S., von der Saal, W., Zimmermann, G., Schneider, G. J. Med. Chem. 2002, 45, 137-142.
48. (b) Hodgkin, E., Andrews-Cramer, K. Modern Drug Discovery 2000, 3, 55-56, 58, 60.
49. (c) Sleep, N. Modern Drug Discovery 2000, 4, 37, 39-40, 42.
50. (d) Godden, J. W., Xue, L., Kitchen, D. B., Stahura, F. L., Schermerhorn, E. J., Bajorath, J. Median, J. Chem. Inf. Comp. Sci. 2002, 42, 885-893.
51. (a) Walters, P. W., Ajay; Murcko, M. A. Curr. Opin. Chem. Biol. 1999, 3, 384-387.
52. (b) Ajay; Walters, P. W., Murcko, M. A. J. Med. Chem. 1998, 41, 3314-3324.
53. (c) Gáive, J., De Julian-Ortiz, J. V., Garcia-Domenech, R. J. Mol. Graph. Mod. 2001, 20, 84-94.
54. McGovern, S. L., Caselli, E., Grigorieff, N., Shoichet, B. K. J. Med. Chem. 2001, 45, 1712-1722.
55. Muegge, I., Heald, S. L., Brittelli, D. J. Med. Chem. 2001, 44, 1841-1846.
56. Sadowski, J., Kubinyi, H. J. Med. Chem. 1998, 41, 3325-3329.
57. (a) Rroudfoot, J. R. Bioorg. Med. Chem. Lett. 2002, 12, 1647-1650.
58. (b) Harvey, A. Drug Discovery Today 2000, 5, 294-300
59. (c) Barrett, D. Biochim. Biophys. Acta 2002, 1587, 224-233.
60. (d) Verpoorte, R. Drug Discovery Today 1998, 3, 232-238.
61. (e) Abel, U., Koch, C., Speitling, M., Hansske, F. G. Curr. Opin. Chem. Biol. 2002, 6, 453-458.
62. For reviews refer to: (a) Swartz, M. E. Analytical techniques in combinatorial chemistry. Marcel Dekker, New York, USA, 2000.
63. (b) Yan, B. Analytical methods in combinatorial chemistry. Technomic, Lancaster, USA, 2000.
64. (c) Schlotterbeck, G., Ross, A., Hochstrasser, R., Senn, H., Kühn, T., Marek, D., Schett, O. Anal. Chem. 2002, 74, 4464-4471.
65. (a) Greene N. Adv. Drug Deliv. Rev. 2002, 54, 417-431.
66. (b) Durham, S. K., Pearl, G. M. Curr. Opin. Drug Disc. Dev. 2001, 4, 110-115.
67. (c) Andrews, C. W., Bennett, L., Yu, L. X. Pharmaceutical Research 2000, 17, 639-644.
68. (d) Lipinski, C. A., Lombardo, F., Dominy, B. W., Feeney, P. J. Adv. Drug Delivery Rev. 1997, 23, 3-25.
69. (e) Cariello, N. F., Wilson, J. D., Britt, B. H., Wedd, D. J., Burlinson, B., Gombar, V. Mutagenesis 2002, 17, 321-329.
70. (f) Clark, D. E. J. Pharma. Sci. 1999, 88, 807-814.
71. (g) Clark, D. E. J. Pharma. Sci. 1999, 88, 815-821.
72. (g) Winiwarter, S., Bonham, N. M., Ax, F., Hallberg, A., Lennernäs, H., Karlén, A. J. Med. Chem. 1998, 41, 4939-4949.
73. (a) Stahl, M., Rarey, M., Klebe, G. Meth. Princ. Med. Chem. 2002, 14, 137-170.
74. (b) Terstappen, G. C., Reggiani, A. Trends Pharmacol. Sci. 2001, 22, 23-26.
75. (c) Schneider, G., Neidhart, W., Giller, T., Schmid, G. Angew. Chem Int. Ed. Engl. 1999, 38, 2894-2896.
76. (d) Detailed information about PHAC1R are provided via: www.callistogen.com.
77. (e) Rarey, M., Dixon, J. S. J. Comp. Aid. Moc. Design 1998, 12, 471-490.
78. (a) Furka, A. Drug Discovery Today 2002, 7, 1-4.
79. (b) Rich, D. H., Dales, N. A., Fan, X., Flentke, G., Glunz, P., Keding, S. J., Ripka, A. S., Satyshur, K. Special Publication -Royal Society of Chemistry 2001, 264, 16-24.
80. (a) Andrews, P. R. 3D QSAR Drug Des. 1993, 13-40.
81. (b) Lloyd, E. J., Andrews, P. R. J. Med. Chem. 1986, 29, 453-62.
82. (c) Andrews, P. R., Craik, D. J., Martin, J. L. J. Med. Chem. 1984, 27, 1648-1657.
83. Teague, S. T., Davis, A. M., Leeson, P. D., Oprea, T. Angew. Chem. Int. Ed. Engl. 1999, 38, 3743-3748.
84. (a) Butina, D., Segall, M. D., Frankcombe, K. Drug Discovery Today 2002, 7, S83-S88.
85. (b) Clark, D. E. Adv. Drug Deliv. Rev. 2002, 54. 253-451.
86. (c) Selick, H. E., Beresford, A. P., Tarbit, M. H. Drug Discovery Today 2002, 7, 109-116.
87. (d) Li, A. P., Segall, M. Drug Discovery Today 2002, 7, 25-27.
88. (e) Li, A. P. Drug Discovery Today 2002, 7, 357-366.
89. (e) Ekins, S., Ring, B. J., Grace, J., McRobie-Belle, D. J., Wrighton, S. A. J. Pharmacol Toxicol. Meth. 2000, 44, 313-324.
90. (f) Topliss, J. G., Fumitaka, Y. J. Med. Chem. 2000, 43, 2575-2585.
91. (a) Martin, Y. C. Il Farmaco 2001, 56, 137-139.
92. (b) Waldman, M., Li, H., Hassan, M. J. Mol. Graph. Mod. 2000, 18, 412-416.
93. (c) Brown, R. D., Hassan, M., Waldman, M. J. Mol. Graph. Mod. 2000, 18, 427-437.
94. (d) Sheridan, R. P., Kearsley, S. K. Drug Discovery Today 2002, 7, 903-911.
95. (a) Albertini, S., Miller, B., Chételat, A. A., Locher, F. Mutation Res. 1997, 392, 187-208.
96. (b) Roche, O., Trube, G., Zuegge, J., Pflimlin, P., Alanine, A., Schneider, G. A. Chem. Bio. Chem. 2002, 3, 101-105.
97. (c) Cavalli, A., Poluzzi, E., De Ponti, F., Recanatini, M. J. Med. Chem. 2002, 45, 3844-3853.
98. (d) Gao, F., Johnson, D. L., Ekins, S., Janiszewski, J., Kelly, K. G., Meyer, R. D., West, M. J. Biomol. Screen. 2002, 7, 373-382.
99. (e) Reasor, M. J., Kacew, S. Exp. Biol. Med. 2001, 226, 825-830.
100. (f) Maron, D. M., Ames, B. N. Mutat. Res. 1983, 113, 173-215.
101. (a) Dolle, R. E. J. Comb. Chem., 2002, 4, 369-418.
102. (b) Dolle, R. E. J. Comb. Chem., 2001, 3, 477-517.
103. (c) Baldino, C. M. J. Comb. Chem. 2000, 2, 89-103.
104. (a) Coates, W. J., Hunter, D. J., MacLachlan, W. S. Drug Discovery Today 2000, 5, 521-527.
105. Everett, J., Gardner, M., Pullen, F., Smith, G. F., Snarey, M., Terrett, N. K. Drug Discovery Today 2001, 6, 779-785.
106. (c) Manly, C. J. J. Autom. Meth. Manag. Chem. 2000, 22, 169-170.
107. (d) Nettekoven M., Thomas A. W. Curr. Med. Chem. 2002, 9, 2179-2190.
108. (e) Macdonald, S. J. F., Smith, P. W. Drug Discovery Today 2001, 5, 947-953.
109. (a) Torphy, T. J., Ruffolo, R. R., Jr. Pharm. News 2001, 8, 50-53.
110. (b) Lawrence R. N. Drug Discovery Today 2002, 7, 645-648.